Short answer
Astrana Health, Inc. (ASTH) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $1.9B (up 524.8% year over year) with net income of $34M.
Q2 2026 key financials · XBRL
- Revenue
- $1.9B
- +524.8% YoY · +100.8% QoQ
- Net income
- $34M
- +1935.4% YoY · +136.7% QoQ
- Operating margin
- 3.2%
- EPS (diluted)
- $0.69
- +1625.0% YoY · +137.9% QoQ
Source: XBRL data from the Astrana Health, Inc. (ASTH) Q2 2026 10-Q on SEC EDGAR. USD.
Astrana Health, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $972.5M, up 49% YoY from $654.8M, including $281.5M from Prospect acquisition
- Operating margin 3.5% vs 3.1% YoY; net income attributable to Astrana $19.7M vs $9.4M
- Adjusted EBITDA $68.9M, up 43% YoY from $48.1M
- Prospect strongest contributor, adding $281.5M revenue; APC weakest, generating $1.3M non-controlling-interest loss
- Borrowings $948.3M vs $408.9M YoY; interest expense $16.0M, up 117% to fund Prospect acquisition
Risk Factors
- No material changes in risk factors from the December 31, 2025 Form 10-K
- Carried-forward healthcare-industry and company-specific risks potentially affecting operations, cash flows, and stock price
- Unknown or currently immaterial risks could materially adversely affect business performance
- Historical financial performance unreliable as an indicator of future results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Astrana Health, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.